Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Clinical trial NCT06090669 · RECRUITING

Trial details

NCT number: NCT06090669
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Inherited Bone Marrow Failure Syndrome Familial Platelet Disorder With Predisposition to Myeloid Malignancies

Start date: 2023-12-19
Primary completion: 2026-10-30
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.